As an example of the power of this approach, an albumin binding domain with high affinity for human serum albumin was used to circumvent the short half-life of Glucagon-like peptide-1 (GLP-1), a promising peptide for the treatment of type 2 diabetes mellitus. Here, ALB is linked to type 2 diabetes mellitus.